Chest pain drug could help fight fetal fungal infection
The approach of stimulating your own immune system to kill the fungus, instead of killing it directly through treatment, is potentially more powerful.
The compound fendiline hydrochloride could be used to stimulate a patient’s own white blood cells to fight the disease more effectively. (Source: Thinkstock Images)A drug, more commonly used in the treatment of angina is a type of chest pain caused by reduced blood flow to heart which could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis, say researchers.
The compound fendiline hydrochloride could be used to stimulate a patient’s own white blood cells to fight the disease more effectively, instead of trying to use drugs that directly kill the fungus itself, the researchers found.
Read More
- Study confirms cardiovascular benefits of semaglutide drug beyond weight loss
- At 95, he had body of 75: Why this fit group qualifies for procedures done on people in their 70s
- Why US plans to drop millions of flies from planes
- 3 doctors recount how patients surprised them by challenging therapies
- When autism is a greater ability than disability: Bengaluru boy runs YouTube music channel. All he needed was encouragement
“Fungi are intrinsically more difficult to target than bacteria, because they are much more closely related, evolutionarily, to humans. Finding an essential pathway in a fungus that you could inhibit, which does not exist in humans, is very difficult,” explained professor Robin May from University of Birmingham.
“Therefore the approach of stimulating your own immune system to kill the fungus, instead of killing it directly through treatment, is potentially more powerful,” he noted.
The study, published in the International Journal of Antimicrobial Agents, propose a role for calcium-channel blockers such as fendiline hydrochloride as potential inhibitors to the survival of Cryptococcus neoformans, the pathogen which causes cryptococcosis, and represent a promising strategy for future anticryptococcal drug design and therapy.
Cryptococcosis neoformans poses a major threat to immunocompromised patients and is a leading killer of HIV patients worldwide.
HIV/AIDS patients are particularly prone to cryptococcal infections, with an estimated overwhelming disease burden of about one million cases of cryptococcal meningitis per year.
The infection process begins with inhalation of infectious agents (spores or dessicated yeasts) resulting in a primary pulmonary infection, which can further disseminate to the central nervous system causing meningitis.
Cryptococci are particularly difficult to treat with anti-fungal agents due to their ability to manipulate and exist within the host’s immune response.
“Considering the poor status of current anticryptococcal drugs, new treatment options for cryptococcosis are much needed,” Rebecca Hall, also from the University of Birmingham, added.
Share
